Bukwang Pharm - Asset Resilience Ratio

Latest as of September 2025: 39.75%

Bukwang Pharm (003000) has an Asset Resilience Ratio of 39.75% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check how strategically is Bukwang Pharm's equity deployed to assess the company's strategic physical and investment asset allocation.

Liquid Assets

₩188.03 Billion
≈ $127.42 Million USD Cash + Short-term Investments

Total Assets

₩472.99 Billion
≈ $320.54 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2007–2024)

This chart shows how Bukwang Pharm's Asset Resilience Ratio has changed over time. See debt-free asset ratio of Bukwang Pharm to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Bukwang Pharm's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 003000 market cap overview.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩188.03 Billion 39.75%
Total Liquid Assets ₩188.03 Billion 39.75%

Asset Resilience Insights

  • Very High Liquidity: Bukwang Pharm maintains exceptional liquid asset reserves at 39.75% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Bukwang Pharm Industry Peers by Asset Resilience Ratio

Compare Bukwang Pharm's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
Drug Manufacturers - Specialty & Generic 0.20%
Huadong Medicine Co Ltd
SHE:000963
Drug Manufacturers - Specialty & Generic 0.05%
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
Drug Manufacturers - Specialty & Generic -0.89%
Walvax BioTech
SHE:300142
Drug Manufacturers - Specialty & Generic 2.20%
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
Drug Manufacturers - Specialty & Generic 6.62%
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436
Drug Manufacturers - Specialty & Generic -2.56%
Celltrion Pharm Inc
KQ:068760
Drug Manufacturers - Specialty & Generic 12.49%
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799
Drug Manufacturers - Specialty & Generic 0.40%

Annual Asset Resilience Ratio for Bukwang Pharm (2007–2024)

The table below shows the annual Asset Resilience Ratio data for Bukwang Pharm.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 10.72% ₩40.00 Billion
≈ $27.11 Million
₩373.18 Billion
≈ $252.90 Million
+10.34pp
2021-12-31 0.38% ₩1.50 Billion
≈ $1.02 Million
₩397.42 Billion
≈ $269.32 Million
-2.19pp
2020-12-31 2.57% ₩10.30 Billion
≈ $6.98 Million
₩400.97 Billion
≈ $271.73 Million
-3.95pp
2014-12-31 6.51% ₩15.43 Billion
≈ $10.46 Million
₩236.82 Billion
≈ $160.49 Million
-2.28pp
2013-12-31 8.79% ₩20.07 Billion
≈ $13.60 Million
₩228.21 Billion
≈ $154.66 Million
+3.73pp
2008-12-31 5.06% ₩11.67 Billion
≈ $7.91 Million
₩230.55 Billion
≈ $156.24 Million
-8.07pp
2007-12-31 13.13% ₩28.24 Billion
≈ $19.14 Million
₩215.02 Billion
≈ $145.71 Million
--
pp = percentage points

About Bukwang Pharm

KO:003000 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$308.58 Million
₩455.34 Billion KRW
Market Cap Rank
#14772 Global
#496 in Korea
Share Price
₩4615.00
Change (1 day)
-3.35%
52-Week Range
₩3225.00 - ₩9600.00
All Time High
₩36947.85
About

Bukwang Pharmaceutical Co., Ltd. develops, produces, and sells pharmaceutical products in South Korea and internationally. It offers its products in oral solid dosage forms, injections, oral solutions, external solutions, and ointments. The company also provides ethical drugs, including drugs for treating diabetic peripheral neuropathy, hypothyroidism, toxic liver disease, chronic hepatitis, live… Read more